{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:55Z","timestamp":1793502715403,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["RD16\/0016"],"award-info":[{"award-number":["RD16\/0016"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["PI15\/00088"],"award-info":[{"award-number":["PI15\/00088"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s10096-018-3361-0","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:35:49Z","timestamp":1534984549000},"page":"2191-2200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands"],"prefix":"10.1007","volume":"37","author":[{"given":"Manuel","family":"D\u00edaz-Ca\u00f1estro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Peria\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Luisa","family":"Martin-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo A.","family":"Fraile-Ribot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ayestar\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Colomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Maci\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Murillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchor","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"3361_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2047-2994-3-32","volume":"3","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V (2014) Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 3:32","journal-title":"Antimicrob Resist Infect Control"},{"key":"3361_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14787210.2017.1251840","volume":"15","author":"M Bassetti","year":"2017","unstructured":"Bassetti M, Carnelutti A, Peghin M (2017) Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti-Infect Ther 15:55\u201365","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"3361_CR3","first-page":"266","volume":"69","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Ceftolozane\/tazobactam activity tested against aerobic gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Inf Secur 69:266\u2013277","journal-title":"J Inf Secur"},{"key":"3361_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1128\/AAC.01104-09","volume":"54","author":"B Moya","year":"2010","unstructured":"Moya B, Zamoramo L, Juan C, Perez JL, Ge Y, Oliver A (2010) Activity of a new cephalosporin, CXA-101 (FR264295), against beta-lactamase-resistant Pseudomonas aeruginosa mutants selected in vitro after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 54:1213\u20131217","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR5","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1128\/AAC.00680-12","volume":"56","author":"B Moy\u00e1","year":"2012","unstructured":"Moy\u00e1 B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S et al (2012) Pan-\u03b2-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 56:4771\u20134778","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J et al (2015) Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60:1462\u20131471","journal-title":"Clin Infect Dis"},{"key":"3361_CR7","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949\u20131956","journal-title":"Lancet"},{"key":"3361_CR8","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1128\/AAC.02136-16","volume":"61","author":"JJ Cast\u00f3n","year":"2017","unstructured":"Cast\u00f3n JJ, De la Torre A, Ruiz-Camps I, Sorl\u00ed ML, Torres V, Torre-Cisneros J (2017) Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 61:2136\u20132116","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/fmb-2017-0018","volume":"12","author":"M Xipell","year":"2017","unstructured":"Xipell M, Bodro M, Marco F, Mart\u00ednez JA, Soriano A (2017) Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane\/tazobactam. Future Microbiol 12:1323\u20131326","journal-title":"Future Microbiol"},{"key":"3361_CR10","doi-asserted-by":"crossref","unstructured":"Kurtzhalts KE, Mergenhagen KA, Manohar A, Berenson CS (2017) Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane\/tazobactam. BMJ Case Rep","DOI":"10.1136\/bcr-2016-217005"},{"key":"3361_CR11","first-page":"1262","volume":"72","author":"A Sousa Dominguez","year":"2017","unstructured":"Sousa Dominguez A, Perez-Rodr\u00edguez MT, Nodar A, Martinez-Lamas L, Perez-Landeiro A, Crespo Casal M (2017) Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane\/tazobactam. J Antimicrob Chemother 72:1262\u20131263","journal-title":"J Antimicrob Chemother"},{"key":"3361_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/cid\/cix182","volume":"65","author":"G Haidar","year":"2017","unstructured":"Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA et al (2017) Ceftolozane-Tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 65:110\u2013120","journal-title":"Clin Infect Dis"},{"key":"3361_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cix014","volume":"65","author":"JM Munita","year":"2017","unstructured":"Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA et al (2017) Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis 65:158\u2013161","journal-title":"Clin Infect Dis"},{"key":"3361_CR14","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/AAC.02462-13","volume":"58","author":"G Cabot","year":"2014","unstructured":"Cabot G, Bruchmann S, Mulet X, Zamorano L, Moy\u00e1 B, Juan C et al (2014) Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58:3091\u20133099","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0895-4356(02)00585-1","volume":"56","author":"V Groot De","year":"2003","unstructured":"De Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56:221\u2013229","journal-title":"J Clin Epidemiol"},{"key":"3361_CR16","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/01.CCM.0000178178.02574.AB","volume":"33","author":"DG Arts","year":"2005","unstructured":"Arts DG, de Keizer NF, Vroom MB, de Jonge E (2005) Reliability and accuracy of sequential organ failure assessment (SOFA) scoring. Crit Care Med 33:1988\u20131993","journal-title":"Crit Care Med"},{"key":"3361_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268\u2013281","journal-title":"Clin Microbiol Infect"},{"key":"3361_CR18","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1128\/AAC.01388-12","volume":"56","author":"G Cabot","year":"2012","unstructured":"Cabot G, Ocampo-Sosa AA, Dom\u00ednguez MA, Gago JF, Juan C, Tubau F et al (2012) Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 56:6349\u20136357","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR19","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1128\/AAC.02676-15","volume":"60","author":"G Cabot","year":"2016","unstructured":"Cabot G, L\u00f3pez-Causap\u00e9 C, Ocampo-Sosa AA, Sommer LM, Dom\u00ednguez M\u00c1, Zamorano L et al (2016) Deciphering the resistome of the widespread Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-genome sequencing. Antimicrob Agents Chemother 60:7415\u20137423","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jac\/dkx424","volume":"73","author":"PA Fraile-Ribot","year":"2018","unstructured":"Fraile-Ribot PA, Cabot G, Mulet X, Peria\u00f1ez L, Mart\u00edn-Pena ML, Juan C et al (2018) Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother 73:658\u2013663","journal-title":"J Antimicrob Chemother"},{"key":"3361_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D Duin Van","year":"2016","unstructured":"Van Duin D, Bonomo RA (2016) Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Clin Infect Dis 63:234\u2013241","journal-title":"Clin Infect Dis"},{"key":"3361_CR22","first-page":"1589","volume":"61","author":"E Barrio-Tofi\u00f1o Del","year":"2017","unstructured":"Del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Cabot G, Rivera A, Benito N, Segura C et al (2017) Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrob Agents Chemother 61:1589\u20131517","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jac\/dkx453","volume":"73","author":"T Giani","year":"2017","unstructured":"Giani T, Arena F, Pollini S, Di Pilato V, D\u2019Andrea MM, Henrici De Angelis L et al (2017) Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane\/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother 73:664\u2013671","journal-title":"J Antimicrob Chemother"},{"key":"3361_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ijantimicag.2015.07.004","volume":"46","author":"M Tato","year":"2015","unstructured":"Tato M, Garcia-Castillo M, Bofarull AM, Canton R (2015) In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. Int J Antimicrob Agents 46:502\u2013510","journal-title":"Int J Antimicrob Agents"},{"key":"3361_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jcph.566","volume":"56","author":"AJ Xiao","year":"2016","unstructured":"Xiao AJ, Miller BW, Huntington JA, Nicolau DP (2016) Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justifiction for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 56:56\u201366","journal-title":"J Clin Pharmacol"},{"key":"3361_CR26","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1128\/AAC.02608-15","volume":"60","author":"WD Oliver","year":"2016","unstructured":"Oliver WD, Heil EL, Gonzales JP, Mehrotra S, Robinett K, Saleeb P et al (2016) Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother 60:1899\u20131901","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/cid\/cit223","volume":"57","author":"C Pe\u00f1a","year":"2013","unstructured":"Pe\u00f1a C, Suarez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V et al (2013) Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis 57:208\u2013216","journal-title":"Clin Infect Dis"},{"key":"3361_CR28","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1128\/CMR.15.4.647-679.2002","volume":"15","author":"JL Mart\u00ednez","year":"2002","unstructured":"Mart\u00ednez JL, Baquero F (2002) Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 15:647\u2013679","journal-title":"Clin Microbiol Rev"},{"key":"3361_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1128\/CMR.00059-12","volume":"26","author":"A Beceiro","year":"2013","unstructured":"Beceiro A, Tom\u00e1s M, Bou G (2013) Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 26:185\u2013230","journal-title":"Clin Microbiol Rev"},{"key":"3361_CR30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/AAC.01586-17","volume":"61","author":"I S\u00e1nchez-Diener","year":"2017","unstructured":"S\u00e1nchez-Diener I, Zamorano L, L\u00f3pez-Causap\u00e9 C, Cabot G, Mulet X, Pe\u00f1a C et al (2017) Interplay among resistance profiles, high-risk clones, and virulence in the Caenorhabditis elegans Pseudomonas aeruginosa infection model. Antimicrob Agents Chemother 61:1586\u20131517","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR31","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijantimicag.2016.02.010","volume":"47","author":"S G\u00f3mez-Zorrilla","year":"2016","unstructured":"G\u00f3mez-Zorrilla S, Juan C, Cabot G, Camoez M, Tubau F, Oliver A et al (2016) Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. Int J Antimicrob Agents 47:368\u2013374","journal-title":"Int J Antimicrob Agents"},{"key":"3361_CR32","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","volume":"43","author":"Y Carmeli","year":"1999","unstructured":"Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999) Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43:1379\u20131382","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR33","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1128\/AAC.01688-10","volume":"55","author":"L Zamorano","year":"2011","unstructured":"Zamorano L, Reeve TM, Juan C, Moya B, Cabot G, Vocadlo DJ et al (2011) AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 55:1990\u20131996","journal-title":"Antimicrob Agents Chemother"},{"key":"3361_CR34","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/jac\/dkx221","volume":"72","author":"S Natesan","year":"2017","unstructured":"Natesan S, Pai MP, Lodise TP (2017) Determination of alternative ceftolozane\/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32\u2009mg\/L. J Antimicrob Chemother 72:2813\u20132816","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-018-3361-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T20:39:45Z","timestamp":1569098385000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-018-3361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3361"],"URL":"https:\/\/doi.org\/10.1007\/s10096-018-3361-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AO has been the recipient of research grants from MSD and has received fees as speaker from MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the research committee of Hospital Universitari Son Espases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since it was an observational study, informed consent was not required","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}